AMPH Stock Amphastar Pharmaceuticals (AMPH, $37.92) Moving Average Convergence Divergence (MACD) Histogram turned positive on January 13, 2025

GET DAILY SIGNALS

Get AI intraday signals

AMPH - Amphastar Pharmaceuticals

MACD signal

View

Odds of UP Trend

Price: $37.92

Daily change: +$1.56 (+4.29%)

Daily volume: 461.9K

Capitalization: $1.8B

Industry: Pharmaceuticals: Other

AMPH sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for AMPH moved below the 200-day moving average on January 10, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for AMPH entered a downward trend on January 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AMPH's RSI Oscillator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 14, 2025. You may want to consider a long position or call options on AMPH as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AMPH just turned positive on January 13, 2025. Looking at past instances where AMPH's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMPH advanced for three days, in of 331 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.265) is normal, around the industry mean (58.228). P/E Ratio (16.692) is within average values for comparable stocks, (89.834). AMPH's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.877). Dividend Yield (0.000) settles around the average of (0.120) among similar stocks. P/S Ratio (3.570) is also within normal values, averaging (19.449).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. AMPH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.